Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects.

European journal of clinical pharmacology - 1 Jun 2012

Yin Ophelia Qi Ping, Mak Valiant Wah Lun, Hu Miao, Fok Benny Siu Pong, Chow Moses Sing Sum, Tomlinson Brian

Abstract excerpt

PURPOSE: Although CYP3A4/5 enzymes play the predominant role in the metabolism of simvastatin and lovastatin, polymorphisms in CYP2D6 were reported to be associated with the cholesterol-lowering effect and/or tolerability of simvastatin. This study was performed to examine whether common CYP2D6 polymorphisms affect the pharmacokinetics of lovastatin, which is taken as the inactive prodrug lovastatin lactone and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asian People

Share to Cytochrome P-450 CYP2D6

Share to Half-Life

Share to Lovastatin

Share to Polymorphism, Genetic

Share to Young Adult

Source

Identifiers

PMID: 22281720
DOI: 10.1007/s00228-011-1202-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects.PMID 22281720Read ↗

Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.Semantic proximity Read ↗

Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers.Semantic proximity Read ↗

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid.Semantic proximity Read ↗

Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.Semantic proximity Read ↗

Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers.Semantic proximity Read ↗

Pharmacokinetics and Genetic Factors of Atorvastatin in Healthy Korean SubjectsSemantic proximity Read ↗

Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.Semantic proximity Read ↗

Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia.Semantic proximity Read ↗

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.Semantic proximity Read ↗

Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients.Semantic proximity Read ↗

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.Semantic proximity Read ↗

The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.